Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia initiated the Phase 4 PRESERVE study to evaluate LUPKYNIS in combination with belimumab, obinutuzumab, or anifrolumab for the treatment of lupus nephritis. The study plans to enroll approximately 150 patients across 50 sites in the US, with the primary endpoint measuring the proportion of patients achieving complete renal response at six months.
Key figures
- Drug Name
- LUPKYNIS
- Phase Of Trial
- Phase 4
- Sites
- 50
- Enrollment
- 150
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.